DMK Pharmaceuticals Corporation (DMKPQ)

DMK Pharmaceuticals Corporation (DMKPQ) Healthcare & Pipeline Overview

DMK Pharmaceuticals Corporation is a clinical-stage neuro-biotechnology company developing therapeutics for allergy, opioid overdose, respiratory, and inflammatory diseases, including lead candidate DPI-125 for opioid use disorder. Operating in the specialty and generic drug manufacturing sector, the company filed for Chapter 11 reorganization in February 2024 and trades on the OTC market.

What Is the Investment Thesis for DMKPQ?

DMK Pharmaceuticals Corporation operates as a clinical-stage neuro-biotechnology entity, with its investment profile significantly shaped by its developmental pipeline and existing commercial products, alongside its recent Chapter 11 filing. A primary value driver is its lead clinical candidate, DPI-125, targeting opioid use disorder, a market with substantial unmet needs and potential for significant therapeutic impact if successful in clinical trials and subsequent regulatory approval. The company also possesses commercial products like SYMJEPI epinephrine injection for anaphylaxis and ZIMHI naloxone injection for opioid overdose, which address critical emergency medical situations. These products, while established, contribute to the company's revenue streams, albeit within a highly competitive landscape. However, the ongoing Chapter 11 reorganization, initiated on February 2, 2024, represents a paramount risk factor and fundamentally alters the investment landscape for DMKPQ. This process introduces significant uncertainty regarding the company's future operational structure, asset disposition, and equity value. The company's financial metrics, including a market capitalization of 1K, a profit margin of -556.7%, and a gross margin of -60.9%, reflect its challenging financial position prior to and during the bankruptcy proceedings. Future growth catalysts are contingent upon successful emergence from bankruptcy, potential advancements of DPI-125 through clinical stages, and sustained market penetration of SYMJEPI and ZIMHI. The low beta of 0.79 suggests relatively lower volatility compared to the broader market, though this is overshadowed by the bankruptcy status. Investors face substantial dilution risk and potential for complete loss of capital given the current financial and legal circumstances.

Based on FMP financials and quantitative analysis

DMKPQ Key Highlights

• Market Capitalization: $0.00B, indicating a distressed valuation following its Chapter 11 filing.
• Profit Margin: -556.7%, reflecting significant operational losses and negative profitability.
• Gross Margin: -60.9%, demonstrating that the cost of goods sold significantly exceeds revenue, even before operating expenses.
• Beta: 0.79, suggesting the stock has historically exhibited lower volatility than the overall market, though this metric's relevance is diminished by the company's bankruptcy status.
• Chapter 11 Reorganization: Filed a voluntary petition for reorganization on February 2, 2024, signaling a critical restructuring phase.

Who Are DMKPQ's Competitors?

DMKPQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DMKPQ's Key Strengths?

• Diverse product pipeline addressing critical medical needs (opioid use disorder, anaphylaxis, opioid overdose).
• Existing FDA-approved commercial products (SYMJEPI, ZIMHI) providing current revenue streams.
• Focus on neuro-biotechnology, a specialized and high-potential therapeutic area.
• Lean operational structure with 11 employees, potentially allowing for agility in R&D.

What Are DMKPQ's Weaknesses?

• Currently undergoing Chapter 11 bankruptcy reorganization, creating significant financial and operational uncertainty.
• Negative profit margin (-556.7%) and gross margin (-60.9%) indicate severe financial distress.
• Small market capitalization ($0.00B) reflects a distressed valuation and limited access to capital.
• Clinical-stage lead product (DPI-125) entails high development risk and long timelines to market.

What Could Drive DMKPQ Stock Higher?

• Chapter 11 Reorganization Proceedings: The company filed for Chapter 11 on February 2, 2024. The ongoing legal process will determine the company's future structure, asset disposition, and potential for emergence.
• Resolution of Bankruptcy Plan: A key catalyst will be the approval and implementation of a reorganization plan by the U.S. Bankruptcy Court, which will outline the path forward for the company.
• Potential for DPI-125 Clinical Trial Updates: Any future announcements regarding the progress or results of clinical trials for its lead candidate, DPI-125, could impact perception, contingent on the company's ability to fund and continue development post-reorganization.
• Commercial Performance of SYMJEPI and ZIMHI: Continued sales and market penetration of its existing FDA-approved products, SYMJEPI and ZIMHI, will be an ongoing factor, though likely overshadowed by the bankruptcy process.

What Are the Key Risks for DMKPQ?

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Chapter 11 Bankruptcy Outcome: The primary risk is the uncertain outcome of the Chapter 11 reorganization, which could result in significant dilution for existing shareholders or complete loss of investment.
• Financial Distress and Liquidity Issues: The company's negative profit and gross margins, coupled with a 1K market cap, indicate severe financial distress and ongoing challenges in maintaining operations and funding R&D.
• Clinical Development Failure for DPI-125: There is inherent risk in drug development, where DPI-125 may fail to achieve desired endpoints in clinical trials or face regulatory hurdles, leading to abandonment or significant delays.
• Intense Competition: The markets for allergy treatments and opioid overdose/use disorder therapies are highly competitive, with larger, better-funded pharmaceutical companies posing a constant threat to market share and pricing.
• Regulatory and Compliance Risks: As a drug manufacturer, DMK Pharmaceuticals faces ongoing risks related to FDA approvals, manufacturing compliance, and potential product recalls, which could incur significant costs and reputational damage.

What Are the Growth Opportunities for DMKPQ?

• Growth opportunity 1: Advancement of DPI-125 for Opioid Use Disorder (OUD) The lead clinical-stage product candidate, DPI-125, targets opioid use disorder, a significant and growing public health crisis. The global market for OUD treatments is substantial, with projections indicating continued expansion due to increasing awareness and treatment initiatives. Successful progression of DPI-125 through clinical trials, culminating in regulatory approval, could unlock a new revenue stream for DMK Pharmaceuticals. This would position the company to address a critical unmet medical need, potentially capturing a share of a market driven by both patient demand and government funding for addiction solutions. The timeline for such an opportunity is long-term, contingent on multi-year clinical development and regulatory review processes.
• Growth opportunity 2: Expansion of SYMJEPI Epinephrine Injection Market Share SYMJEPI epinephrine injection addresses the emergency treatment of anaphylaxis, a life-threatening allergic reaction. The market for epinephrine auto-injectors is robust, driven by increasing allergy prevalence and the necessity for immediate intervention. While competitive, opportunities exist for DMK Pharmaceuticals to expand SYMJEPI's market share through strategic partnerships, improved distribution channels, or differentiated marketing efforts, assuming the company successfully navigates its Chapter 11 proceedings. Enhancing patient and prescriber awareness of SYMJEPI's features could contribute to modest revenue growth in the near to medium term, provided the company can maintain supply and competitive pricing.
• Growth opportunity 3: Increased Adoption of ZIMHI Naloxone Injection ZIMHI naloxone injection is a critical product for treating opioid overdose, a persistent and devastating public health issue. The demand for naloxone products continues to rise as communities and healthcare providers intensify efforts to combat the opioid crisis. Opportunities exist for DMK Pharmaceuticals to increase ZIMHI's adoption through expanded access programs, partnerships with first responders and public health organizations, and educational initiatives. A successful strategy could lead to increased sales volume in the medium term, leveraging the ongoing need for effective overdose reversal medications. The competitive landscape for naloxone products is intense, requiring strategic positioning.
• Growth opportunity 4: Potential for Pipeline Diversification Post-Reorganization While currently focused on allergy, opioid overdose, respiratory, and inflammatory diseases, a successful reorganization could theoretically enable DMK Pharmaceuticals to explore new product candidates or therapeutic areas. This diversification could involve in-licensing novel compounds, acquiring smaller biotech assets, or initiating new internal research programs. Such a strategy would aim to reduce reliance on existing products and the lead candidate, DPI-125, by broadening the company's therapeutic reach. This is a longer-term growth opportunity, highly dependent on the company's financial health and strategic direction post-bankruptcy, and would require significant capital investment and R&D capabilities.
• Growth opportunity 5: Strategic Partnerships and Collaborations Given its clinical-stage pipeline and existing commercial products, DMK Pharmaceuticals could pursue strategic partnerships or collaborations with larger pharmaceutical companies. These alliances could provide much-needed capital, R&D expertise, and broader commercialization capabilities, especially for products like DPI-125. A partnership could accelerate development timelines, facilitate market access, and share the financial burden and risks associated with drug development and commercialization. Such collaborations could be a vital pathway to growth and stability, particularly in the context of the company's Chapter 11 status, offering a potential lifeline for future operations and product success in the medium to long term.

What Opportunities Does DMKPQ Have?

• Successful emergence from Chapter 11 could provide a restructured financial foundation for future operations.
• Advancement and potential approval of DPI-125 could tap into the growing market for opioid use disorder treatments.
• Expansion of market share for existing products like SYMJEPI and ZIMHI through strategic initiatives.
• Potential for strategic partnerships or licensing deals to fund development and commercialization efforts.

What Threats Does DMKPQ Face?

• Uncertainty and potential negative outcomes from the ongoing Chapter 11 bankruptcy proceedings, including asset liquidation or equity wipeout.
• Intense competition in the specialty and generic drug markets from larger, well-funded pharmaceutical companies.
• Regulatory hurdles and potential delays in the clinical development and approval process for DPI-125.
• Market acceptance and reimbursement challenges for new and existing products.

What Are DMKPQ's Competitive Advantages?

• Proprietary clinical-stage product candidate, DPI-125, targeting opioid use disorder, offers potential future market exclusivity if successfully developed and approved.
• Existing FDA-approved commercial products, SYMJEPI and ZIMHI, represent established market access and regulatory hurdles for new entrants.
• Specialized expertise in neuro-biotechnology and drug development for specific therapeutic areas.
• Patent protection (if applicable and current) for its formulations and delivery systems for SYMJEPI and ZIMHI.

What Does DMKPQ Do?

DMK Pharmaceuticals Corporation, originally known as Adamis Pharmaceuticals Corporation until its name change in September 2023, is a clinical-stage neuro-biotechnology company based in San Diego, California. The company focuses on the development and commercialization of pharmaceutical products across several therapeutic areas, including allergy, opioid overdose, respiratory conditions, and inflammatory diseases. Its strategic approach involves advancing a pipeline of product candidates aimed at addressing significant unmet medical needs. A cornerstone of DMK Pharmaceuticals' pipeline is DPI-125, its lead clinical-stage product candidate. This compound is specifically indicated for the treatment of opioid use disorder, a critical public health challenge. Beyond its developmental pipeline, DMK Pharmaceuticals also has commercialized products in its portfolio. These include SYMJEPI epinephrine injection, designed for the emergency treatment of severe allergic reactions (anaphylaxis) triggered by various factors such as insect stings, foods, drugs, or idiopathic and exercise-induced causes. This product provides an important emergency response tool for individuals at risk of anaphylaxis. Another key product is ZIMHI naloxone injection, which is indicated for the rapid treatment of opioid overdose. Naloxone is a crucial medication in combating the opioid crisis, acting as an opioid antagonist to reverse the effects of opioid toxicity. The company's focus on both emergency treatments and a developmental candidate for opioid use disorder highlights its commitment to addressing acute and chronic aspects of public health challenges. Despite its product portfolio and development efforts, DMK Pharmaceuticals Corporation initiated a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on February 2, 2024, along with its affiliates. This significant event marks a pivotal point in the company's operational and financial trajectory, impacting its future market position and strategic direction within the specialty and generic drug manufacturing industry. The company maintains a lean operational structure with 11 employees, reflecting its clinical-stage focus and ongoing reorganization efforts.

What Products and Services Does DMKPQ Offer?

• Develops and commercializes products in therapeutic areas including allergy, opioid overdose, respiratory, and inflammatory diseases.
• Advances DPI-125, a lead clinical-stage product candidate for the treatment of opioid use disorder.
• Manufactures SYMJEPI epinephrine injection for the emergency treatment of severe allergic reactions (anaphylaxis).
• Produces ZIMHI naloxone injection, used for the treatment of opioid overdose.
• Operates as a clinical-stage neuro-biotechnology company.
• Focuses on specialty and generic drug manufacturing within the healthcare sector.
• Manages a small team of 11 employees, indicating a lean operational structure.

How Does DMKPQ Make Money?

• Generates revenue through the sale of commercialized pharmaceutical products such as SYMJEPI epinephrine injection and ZIMHI naloxone injection.
• Invests in research and development for clinical-stage product candidates like DPI-125, with the aim of future commercialization and revenue generation upon regulatory approval.
• Potentially seeks licensing agreements or partnerships for its pipeline assets to fund development and share commercialization efforts.
• Operates within a regulatory framework requiring extensive clinical trials and approvals for new drug candidates.

What Industry Does DMKPQ Operate In?

DMK Pharmaceuticals Corporation operates within the highly specialized and competitive Drug Manufacturers - Specialty & Generic industry, a segment of the broader Healthcare sector. This industry is characterized by rigorous regulatory pathways, significant research and development investments, and intense competition from both large pharmaceutical companies and other biotechnology firms. The market for specialty drugs, particularly in areas like opioid use disorder and emergency anaphylaxis treatment, is driven by evolving medical needs, demographic shifts, and public health crises. For instance, the ongoing opioid crisis underscores the critical demand for effective treatments like DPI-125 and overdose reversal agents like ZIMHI. Similarly, epinephrine auto-injectors like SYMJEPI address a persistent need for emergency allergy management. However, the generic drug segment faces continuous pricing pressure and competition from multiple manufacturers. DMK Pharmaceuticals' position as a clinical-stage company with a limited product portfolio and recent bankruptcy filing places it in a challenging competitive landscape, where larger, more financially robust players often dominate market share and R&D capabilities. The company's ability to navigate this environment is heavily dependent on its reorganization success and pipeline advancement.

Who Are DMKPQ's Key Customers?

• Healthcare providers, including hospitals, clinics, and emergency medical services, who prescribe and administer SYMJEPI and ZIMHI.
• Patients suffering from severe allergies requiring emergency epinephrine, or individuals at risk of opioid overdose.
• Pharmacies and distributors that stock and dispense the company's commercial products.
• Potentially government agencies and public health initiatives focused on combating the opioid crisis.

How DMK Pharmaceuticals Corporation Is Valued

DMK Pharmaceuticals Corporation carries a market capitalization of 1K, placing it in the micro-cap category. Relative to its peer group, DMKPQ's quantitative score of 61/100 is roughly in line with the peer average of 66/100.

Company Profile

DMK Pharmaceuticals Corporation operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Eddie Wabern Glover. DMKPQ has traded publicly since 1995.

F-Score 2/9Financial Health

DMK Pharmaceuticals Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

FY2026 estForward Outlook

Wall Street analysts project DMK Pharmaceuticals Corporation revenue of about $29.5M for fiscal 2026, with EPS near $-0.17.

DMKPQ Financials

DMKPQ Latest News

No recent news available for DMKPQ.

DMKPQ Analyst Consensus

DMKPQ MoonshotScore

DMK Pharmaceuticals Corporation Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources